Trials / Completed
CompletedNCT01984723
EVP-6124 Renal Impairment Study
A Multi-Center, Open-Label Phase I Study to Investigate the Effect of Different Degrees of Renal Impairment on the Single-Dose Pharmacokinetics of EVP-6124 in Patients With Renal Impairment Compared to Subjects With Normal Renal Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- FORUM Pharmaceuticals Inc · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the pharmacokinetics of EVP-6124 and metabolites after a single oral dose in subjects with mild, moderate and severe renal impairment compared with subjects with normal renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Experimental: EVP-6124 |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2014-02-01
- First posted
- 2013-11-15
- Last updated
- 2015-08-26
Locations
2 sites across 2 countries: Czechia, Hungary
Source: ClinicalTrials.gov record NCT01984723. Inclusion in this directory is not an endorsement.